Researching Alzheimer's Medicines: Setbacks and Stepping Stones

New Medicines Yield Significant Progress against Serious Diseases

PhRMA Statement on Flawed British Medical Journal Analysis

Washington, D.C. (August 9, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today on the recent analysis in the British Medical Journal:

Infographic: Building a 21st Century Workforce

Selected Medicines in Development for Mental Illness

Anxiety (Social Phobia) – Anxiety disorders affect more than 40 million adults in the U.S., with about 15 million of those suffering from acute social phobia, according to the National Institute of Mental Health.  A potential medicine in development is part of a new class of psychotropic pherines.  The drug, which has a unique mechanism of action, is administered in an intranasal spray and acts with rapid-onset on peripheral receptors from nasal chemosensory neurons that act on the hypothalamic-limbic system in the brain, which is thought to be the primary center of emotion

Medicines in Development for Mental Illnesses - 2012 Report

PhRMA Statement on Patent Reform - 2011

Washington, D.C. (June 23, 2011) — The Pharmaceutical Research and Manufacturers of America Deputy Vice President Karl Uhlendorf today released the following statement regarding patent reform:

Cumulative Gains Are Building Blocks to Incredible Progress in War Against Cancer

Washington, D.C. (June 12, 2012) — Following Food and Drug Administration (FDA) approval of a new cancer medicine, it often takes years of additional research to fully understand the value of the medicine to patients, according to "Recognizing Value in Oncology Innovation," a new paper released by the Boston Healthcare Associates (BHA).

Recognizing Value in Oncology Innovation Report

Recognizing Value In Oncology Innovation Executive Summary


Subscribe to RSS - Innovation